+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuralgia Treatment Market - Global Forecast 2026-2032- Product Image
Neuralgia Treatment Market - Global Forecast 2026-2032- Product Image
New

Neuralgia Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5146088
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuralgia treatment market is experiencing notable evolution as clinicians, manufacturers, and payers respond to shifting therapeutic landscapes, supply chain pressures, and new stakeholder demands. Senior executives in healthcare must adapt to a dynamic environment where clinical innovations, regulatory reforms, and operational realities intertwine to shape patient care and commercial outcomes.

Market Snapshot

The neuralgia treatment market grew from USD 1.35 billion in 2025 to USD 1.53 billion in 2026, with expectations for continued expansion at a compound annual growth rate of 13.24%, reaching USD 3.24 billion by 2032. This growth highlights substantial shifts in care delivery, the emergence of innovative therapeutic modalities, and heightened strategic activity among global and regional industry stakeholders. Market participants face increasing complexity in meeting evolving patient needs, payer expectations, and regulatory prerequisites, creating fertile ground for targeted innovation and operational adaptation.

Scope & Segmentation

  • Treatment Modalities: Includes both pharmacological options—such as anticonvulsants, antidepressants, local anesthetics, NSAIDs, opioids, topical agents—and non-pharmacological interventions like neuromodulation, acupuncture, and physical therapy.
  • Delivery Modes: Covers injectable, oral, topical, and transdermal administration, each shaping distinctive patient adherence trends and clinical workflows.
  • End User Dynamics: Addresses segmentation across hospitals, ambulatory surgical centers, specialty clinics, and home healthcare, highlighting their unique procurement cycles and workflow requirements.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy are analyzed to gauge impact on patient access, support services, and reimbursement strategies.
  • Indications: Focuses on chemotherapy-induced neuralgia, diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia, with tailored clinical development and value proposition requirements for each.
  • Drug Classes: Examines differentiated safety profiles, titration needs, and monitoring demands across primary drug classes utilized in neuralgia therapy.
  • Regions: Analysis spans Americas, Europe, Middle East & Africa, and Asia-Pacific, addressing regulatory variations, payer models, and care delivery preferences.
  • Technologies: Addresses the role of digital therapeutics, remote patient monitoring, and device-based interventions in treatment advances.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Personalization of therapy is advancing through greater use of biomarker-driven stratification and phenotype-specific treatment pathways, enhancing alignment with patient subgroups and optimizing care outcomes.
  • Integration of multimodal regimens and technology-enabled models, including digital health and remote monitoring, is shifting neuralgia care beyond traditional hospital environments and improving early intervention opportunities.
  • Regulatory landscapes are recalibrating, with adaptive trial designs and accelerated reviews responding to unmet medical needs, fostering faster market entry for novel therapies.
  • Payer expectations now emphasize real-world evidence and outcome-based contracting, prompting manufacturers to demonstrate long-term functional improvement and patient-reported benefits.
  • Cross-functional procurement strategies are gaining prominence, as health systems increasingly prioritize product supply continuity, contract flexibility, and source diversification to manage risks in uncertain trade environments.
  • Manufacturer competitiveness relies on blending product and service innovation, incorporating patient engagement tools, training, and post-launch support to secure provider buy-in and adherence.

Tariff Impact and Supply Chain Adaptations

Recent tariff adjustments and trade disruptions have amplified scrutiny of neuralgia therapy supply chains. These changes prompted manufacturers to intensify nearshoring, diversify supplier bases, and embed contractual safeguards for procurement volatility. Health systems and specialty clinics are, in turn, favoring products with demonstrably stable or domestic supply channels. Accurate product classification and customs compliance, driven by close collaboration between regulatory and commercial teams, have become essential to mitigate downstream care interruptions.

Methodology & Data Sources

This report employs a rigorous methodology combining primary interviews with clinicians, payers, procurement professionals, and technology developers; systematic literature review of peer-reviewed publications and official guidance; and scenario analysis to examine operational impacts and validate findings. Ongoing validation with clinical and commercial advisors ensures actionable, cross-stakeholder relevance throughout the research process.

Why This Report Matters

  • Synthesizes regulatory and commercial developments for practical decision support in a rapidly evolving neuralgia therapy landscape.
  • Provides actionable segmentation for product development, commercialization, and evidence-generation strategies across healthcare sectors.
  • Delivers clarity on adapting to payer evolution, procurement agility, and personalized medicine challenges for optimal market positioning.

Conclusion

Success in the neuralgia treatment market will rely on aligning innovation with operational resilience and stakeholder evidence needs. Companies that prioritize personalization, robust real-world data, and resilient supply strategies will shape the future of neuralgia care and commercialization.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Neuralgia Treatment Market, by Treatment Type
8.1. Non Pharmacological
8.1.1. Acupuncture
8.1.2. Neuromodulation
8.1.3. Physical Therapy
8.2. Pharmacological
9. Neuralgia Treatment Market, by Delivery Mode
9.1. Injectable
9.2. Oral
9.3. Topical
9.4. Transdermal
10. Neuralgia Treatment Market, by Drug Class
10.1. Anticonvulsants
10.2. Antidepressants
10.3. Local Anesthetics
10.4. NSAIDs
10.5. Opioids
10.6. Topical Agents
11. Neuralgia Treatment Market, by End User
11.1. Ambulatory Surgical Centers
11.2. Home Healthcare
11.3. Hospitals
11.4. Specialty Clinics
12. Neuralgia Treatment Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Neuralgia Treatment Market, by Indication
13.1. Chemotherapy Induced Neuralgia
13.2. Diabetic Neuropathy
13.3. Postherpetic Neuralgia
13.4. Trigeminal Neuralgia
14. Neuralgia Treatment Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Neuralgia Treatment Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Neuralgia Treatment Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Neuralgia Treatment Market
18. China Neuralgia Treatment Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Eli Lilly and Company
19.7. GlaxoSmithKline plc
19.8. Grünenthal GmbH
19.9. Johnson & Johnson
19.10. Novartis AG
19.11. Pfizer Inc.
19.12. Sanofi S.A.
19.13. Teva Pharmaceutical Industries Ltd.
19.14. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 120. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 122. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 123. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 125. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 136. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 138. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 139. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 140. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 141. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 155. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 156. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 157. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 158. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 161. GCC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. GCC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 163. GCC NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 164. GCC NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 165. GCC NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 166. GCC NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. GCC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. GCC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 177. BRICS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. BRICS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 179. BRICS NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 180. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 181. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 182. BRICS NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. BRICS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 185. G7 NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. G7 NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 187. G7 NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 188. G7 NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 189. G7 NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 190. G7 NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. G7 NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. G7 NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 193. NATO NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. NATO NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 195. NATO NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 196. NATO NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 197. NATO NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 198. NATO NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 199. NATO NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. NATO NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 210. CHINA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 211. CHINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 212. CHINA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 213. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 214. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 215. CHINA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 217. CHINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Neuralgia Treatment market report include:
  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grünenthal GmbH
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.53 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.24 Billion
Compound Annual Growth Rate13.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Post Herpetic Neuralgia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Post Herpetic Neuralgia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Neuralgia Treatment - Global Strategic Business Report - Product Image

Neuralgia Treatment - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Neuralgia Treatment Market Report 2025 - Product Image

Neuralgia Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Neuralgia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Neuralgia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
2025 Global Forecast for Post Herpetic Neuralgia Treatment Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Post Herpetic Neuralgia Treatment Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From

About the Neuralgia Drug Market

Neuralgia is a type of chronic pain that affects the nerves of the central nervous system. It is often caused by nerve damage or irritation, and can be difficult to treat. Neuralgia drugs are used to reduce the pain associated with this condition. These drugs work by blocking the transmission of pain signals from the affected nerves to the brain. Commonly used neuralgia drugs include anticonvulsants, antidepressants, and opioids. These drugs can be taken orally, injected, or applied topically. The neuralgia drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in this market include Pfizer, GlaxoSmithKline, Novartis, Merck, and Johnson & Johnson. These companies are constantly developing new drugs and treatments to improve the quality of life for those suffering from neuralgia. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.